‘Disney To Raise Price On Ad-Free Disney+ To $13.99 Per Month Starting October 12’ – CNBC
https://www.cnbc.com/2023/08/09/disney-to-raise-disney-price-for-ad-free-plan-in-september.html
Bird Global Appoints Michael Washinushi As Interim CEO, Effective Immediately
Bird Global, Inc. (NYSE:BRDS), a leader in environmentally friendly electric transportation, today announced the appointment of Michael Washinushi as interim Chief Executive Officer (CEO), effective immediately. Mr.
Innoviz Announces $60M Public Offering Of Ordinary Shares
Innoviz Technologies Ltd. (NASDAQ:INVZ) ("Innoviz"), a leading Tier-1 direct supplier of high-performance, automotive grade LiDAR sensors and perception software, today announced
Avid Technology Enters into Definitive Agreement To Be Acquired By An Affiliate Of STG For $1.4B; Stockholders to Receive $27.05 Per Share In Cash
Stockholders to Receive $27.05 Per Share in Cash
Transaction Represents 32.1% Premium to Avid's Unaffected Share Price on May 23, 2023
Avid to Become a Privately Held Company Upon
TiVo Announces Sharp As Second Major Partner To Adopt TiVo’s Independent Media Platform
TiVo, the company that brings entertainment together and a wholly-owned subsidiary of Xperi Inc. (NYSE:XPER), and Sharp announced today that Sharp will launch smart TVs Powered by TiVo™ as part of a multi-year,
Cancer Discovery Publishes Preclinical And Initial Clinical Data For MRTX1719 To Treat MTAP-Deleted Cancers through Novel Approach To MTA-Cooperative PRMT5 Inhibition
The detailed pharmacological and mechanistic characterization of MRTX1719 demonstrates that blocking PRMT5-MTA complex is a rational and differentiated approach to treat cancers harboring MTAP deletion
Partial responses
Galera Receives Complete Response Letter From U.S. FDA for Avasopasem Manganese; The Co Intends To Request A Type A Meeting With The FDA To Understand The FDA’s Rationale For Its Decision
The Company remains committed to its goal of bringing avasopasem to patients and intends to meet with FDA as soon as possible to discuss potential next steps
Galera will take actions to extend its cash runway and
Enhabit Sees FY23 EPS $0.28-$0.46 Vs $0.65 Est.; Revenue $1.057B-$1.065B Vs $1.11B Est.
GUIDANCE
The Company revised its full-year 2023 guidance as follows:
($ in millions, except per share data)
Full-Year 2023
2023
Noodles & Company Sees FY23 EPS $(0.11)-$0.00 Vs $0.15 Est.; Revenue $500M-$510M Vs $538.41M Est.
Business Outlook:
Based upon management's current assessment following second quarter results, the Company has revised guidance related to its 2023 performance. The following is now expected
Verra Mobility Sees FY23 EPS $1.00-$1.10 Vs $1.08 Est.; Revenue $800M-$810M Vs $792.66M Est.
2023 Full Year Guidance
Any guidance that we provide is subject to change as a variety of factors can affect actual operating results. Certain of the factors that may impact our actual operating results